Abstract: Conjugates of drugs suitable for use in the treatment of inflammatory bowel disease and phospholipids, and their use in the treatment of inflammatory bowel disease, are disclosed. The disclosed conjugates serve as targeted prodrugs which are suitable for oral administration, and which are capable of releasing the drug selectively at the diseased tissue upon activation by PLA2.
July 11, 2016
Date of Patent:
July 21, 2020
Ben-Gurion University of the Negev Research and Development Authority